por John R. Fischer
, Senior Reporter | July 26, 2022
Exo has acquired Medo and will integrate the latter's AI technology with its Exo Works ultrasound platform.
Medical imaging provider Exo is acquiring Medo and integrating its Sweep AI technology on to its ultrasound software, Exo Works, to allow inexperienced users to perform ultrasound faster.
The intuitive point-of-care workflow system streamlines documentation, billing and quality assurance from one platform, in under 60 seconds. It works with almost all point-of-care ultrasound devices, and can securely connect to the most common EMR and PACS systems.
Sweep AI utilizes automated acquisition and interpretation to lower the expertise required for ultrasound imaging. It also uses two FDA-cleared algorithms and a library of millions of ultrasound images and longitudinal health data to simplify scanning. This will allow Exo to accelerate point-of-care ultrasound adoption and expand early disease detection for faster treatment.
The addition of Medo brings Exo one step closer to making ultrasound imaging as easy as taking a photo on a smartphone, Exo CEO and founder Sandeep Akkaraju told HCB News. "The ultimate vision is to use the combined power of Exo and Medo's AI to enable more people to use medical imaging for faster and more accurate diagnosis and treatment for every patient. This could be used for a significant number of critical conditions, affecting cardiac, lung and abdominal health as examples."
In August 2021, Exo raised $220 million
in funding for commercializing Exo Works. It also plans to commercialize a handheld ultrasound device with new technology that facilitates quality imaging at a fraction of the cost of a cart-based system. A hardware solution will scan the entire body and is expected to be widely used in emergency departments, rural clinics and community hospitals.
Medo also has partners across the globe, including Canada, where the company is located. These practices will clinically validate and adopt the technology. "Partnering with healthcare institutions is essential in acquiring medical imaging for AI and validating its development. Medo has strong partnerships with health systems worldwide, including top healthcare institutions in Asia and Canada. Exo is continuing to build relationships with these providers," said Akkaraju.
In addition to Medo, Exo has partnered with Henry Ford Innovations
, the commercialization arm of Henry Ford Health. HFI will combine its medical expertise with Exo’s technology to make ultrasound simpler to use for point-of-care.
"Exo’s powerful hardware and workflow technologies, and Medo’s AI will dramatically reduce the challenges that have long held back the widespread adoption of point-of-care ultrasound,” said Dornoosh Zonoobi, CEO of Medo, in a statement.
Financial details were not disclosed.